Skip to main content

Table 3 American College of Rheumatology Core Components and Acute Phase Reactants for Patients Identified as ACR20 Non-responders at Week 12

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

ACR Core Reactant Components and Acute Phase ACR20 Non-responder at Week 12
(N = 321/772, 41.6%)
   Baseline Week 12 Change % Change
ACR Core Set Tender joint count (0-68 scale) 14.4 ± 7.8 10.6 ± 7.9 -3.8 ± 6.2 -21.6 ± 57.3%
  Swollen joint count (0-66 scale) 12.9 ± 5.2 9.1 ± 5.7 -3.8 ± 5.0 -28.1 ± 41.4%
  Patient's assessment of pain, mm (0-100 mm VAS)a 64.7 ± 24.3 55.3 ± 26.3 -9.1 ± 25.1 7.1 ± 275%
  Patient's global assessment of disease activity, mm (0-100 mm VAS)b 64.6 ± 24.1 54.9 ± 26.6 -9.5 ± 25.1 3.3 ± 191%
  Physician's global assessment of disease activity, mm (0-100 mm VAS)b 63.1 ± 17.8 42.7 ± 24.1 -20.5 ± 23.0 -31.1 ± 38.2%
  HAQ-DI score (0-3 scale)c 1.6 ± 0.6 1.4 ± 0.7 -0.2 ± 0.4 -14.7 ± 37.1%
Acute Phase Reactant ESR (mm/h) normal value < 20 mm/h 29.6 ± 23.7 23.5 ± 21.6 -5.9 ± 15.8 -9.2 ± 76.8%
  1. All values are mean ± standard deviation.
  2. a0 = no pain and 100 = severe pain.
  3. b0 = no disease activity and 100 = extreme disease activity.
  4. c0 = no difficulty and 3 = unable to perform activity.
  5. ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.